Key result
Ticagrelor significantly increased the incidence of TIMI grade III blood flow compared to clopidogrel (98.0% vs 83.3%) in acute STEMI patients undergoing emergency percutaneous coronary intervention.
Why the study?
Does ticagrelor improve TIMI blood flow and platelet inhibition compared to clopidogrel in acute STEMI patients undergoing emergency PCI?
RCT (n=97)
Computer-generated random number sequence
No
Does ticagrelor improve TIMI blood flow and platelet inhibition compared to clopidogrel in acute STEMI patients undergoing emergency PCI?
Answers are grounded in this paper and cite their sources.
May support ticagrelor over clopidogrel for STEMI emergency PCI; hypothesis-generating and requires randomized confirmation.
) decreased significantly in the ticagrelor group versus that in the clopidogrel group. In conclusion, ticagrelor significantly improved TIMI blood flow and had a better antiplatelet effect than clopidogrel in STEMI patients undergoing an emergency PCI.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2019) conducted an RCT in Acute ST-segment elevation myocardial infarction (STEMI) (n=97). Ticagrelor vs. Clopidogrel (600 mg loading dose, then 75 mg once daily) was evaluated on Incidence of TIMI grade III blood flow (p=0.016). Ticagrelor significantly increased the incidence of TIMI grade III blood flow compared to clopidogrel (98.0% vs 83.3%) in acute STEMI patients undergoing emergency percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: